Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corcept Therapeutics Inc. (CORT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain their contents. Corcept is a Nasdaq-listed, commercial-stage pharmaceutical company focused on cortisol modulation in endocrinologic, oncologic, metabolic and neurologic disorders, and its filings offer detailed insight into this business.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Corcept describes its commercial activities with Korlym, which it identifies as the first FDA-approved medication for patients with endogenous hypercortisolism, as well as its research and development programs in hypercortisolism, solid tumors, ALS and liver disease. These periodic reports typically discuss product revenue, research and development spending, and risks related to drug development and regulation.
Current reports on Form 8-K, some of which are summarized in the data provided, disclose material events such as quarterly financial results, submission and FDA acceptance of New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application to the European Medicines Agency, and the receipt of an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Other 8-K filings describe corporate developments, including changes to distribution agreements for Korlym and board-level changes accompanied by consulting arrangements.
On this page, users can review Corcept’s Forms 10-K, 10-Q and 8-K as they are made available from EDGAR, while AI-generated highlights point out key topics such as clinical trial updates, regulatory milestones, revenue trends and significant contracts. The filings section also surfaces exhibits referenced in 8-Ks, helping investors and researchers understand how Corcept’s cortisol-modulation strategy, pipeline progress and commercial operations are reflected in its official regulatory reporting.
Corcept Therapeutics (CORT) Chief Development Officer William Guyer reported transactions on 11/05/2025. He exercised 20,000 stock options at $21.65 and sold a total of 20,000 shares in multiple trades, including 6,536 shares at a weighted average of $74.7489, 13,164 shares at $75.6365, and 300 shares at $76.28. Following these trades, he directly owned 5,287 shares and held 290,000 derivative securities (options) afterward. The transactions were made under a Rule 10b5-1 plan adopted on November 27, 2024.
Corcept Therapeutics (CORT) insider transaction: Chief Accounting & Technology Officer Joseph Douglas Lyon exercised 5,000 stock options at $13.56 per share on 11/03/2025 and sold 5,000 common shares the same day at a weighted average price of $73.6489. The filing notes sale prices ranged from $73.47 to $73.945 per share.
Following these transactions, he beneficially owned 10,277 shares directly. The filing also notes unvested restricted stock awards granted on 12/02/2024 (215 shares), 03/03/2025 (216 shares), 06/02/2025 (749 shares), and 09/02/2025 (200 shares), which vest 100% on the one-year anniversary of each grant, subject to conditions. The option exercised was fully exercisable and relates to a grant expiring 02/07/2030, with 16,571 derivative securities beneficially owned afterward.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/30/2024.
Corcept Therapeutics (CORT) CEO and director Joseph K. Belanoff reported open‑market sales totaling 40,000 shares pursuant to a Rule 10b5‑1 trading plan adopted on November 26, 2024.
The trades occurred on November 3, 2025 (11,218 shares at
He has voting power over the trust shares pursuant to voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics (CORT) officer Sean Maduck exercised stock options for 20,000 shares at $8.27 on 11/03/2025, then sold 20,000 shares at a weighted average price of $73.9908. The sale was made pursuant to a Rule 10b5-1 plan adopted on 09/05/2024.
After these transactions, he directly holds 7,904 shares and 261,986 stock options. Indirect holdings are 59,717 shares via the Sean and Molly Maduck Living Trust, 40,000 shares via the SNM 2025 GRAT, and 10,000 shares via Duckhill Capital, LLC.
Corcept Therapeutics (CORT) reported Q3 2025 results. Net product revenue was $207.6 million, up from $182.5 million a year ago, driven by a 42.5% increase in sales volume, partly offset by a 20.2% lower average price due to higher authorized‑generic mix; an August 2025 price increase partially offset the decline. Cost of sales rose to $4.6 million, including a $1.0 million inventory write‑off.
Operating expenses expanded as the company invests behind pipeline and commercialization: R&D was $68.8 million and SG&A was $124.0 million. Income from operations fell to $10.2 million (from $46.6 million). Net income was $19.7 million versus $47.2 million, with diluted EPS of $0.16 versus $0.41. Cash, cash equivalents and marketable securities totaled $524.2 million as of September 30, 2025. Year‑to‑date, the company repurchased 2.6 million shares for $172.9 million; $11.4 million remains authorized. Shares outstanding were 105,188,217 as of October 23, 2025.
Key pipeline milestones: the FDA accepted the NDA for relacorilant in hypercortisolism with a PDUFA date of December 30, 2025, and accepted the NDA for relacorilant plus nab‑paclitaxel in platinum‑resistant ovarian cancer with a PDUFA date of July 11, 2026. A Q3 tax benefit reflected newly enacted U.S. legislation allowing immediate expensing of certain R&D.
Corcept Therapeutics (CORT) furnished an 8-K stating it issued a press release with financial results for the quarter ended September 30, 2025 and a corporate update. The release, dated November 4, 2025, is attached as Exhibit 99.1.
The information under Items 2.02 and 7.01 is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless expressly stated.
Corcept Therapeutics (CORT) director reports option exercise and sale. On 10/10/2025, the reporting person exercised 2,200 stock options at $14.08 per share and sold 2,200 shares at $87.54, both reported as direct holdings. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 1, 2024.
Following these transactions, common stock directly held was 0 shares. The filer reports 1,100 derivative securities (stock options) remaining directly owned, which are fully exercisable and carry an expiration date of 08/20/2028.
Corcept Therapeutics (CORT) terminated its distribution services agreement with Optime Care, delivering notice on October 10, 2025, with termination effective January 8, 2026. Optime had served as a specialty pharmacy distributor for Korlym and Corcept’s authorized generic mifepristone, handling pharmacy operations, patient access, reimbursement support, claims, A/R, and reporting.
The agreement, originally dated August 4, 2017 and amended and restated April 1, 2024, had been extended through March 31, 2027 with automatic three-year renewals. Corcept previously informed Optime that, under its contractual rights, Optime’s exclusivity ended on September 15, 2025. The contract permitted termination for convenience by Corcept with 90-days advance notice, as well as customary remedies for material breach.
Corcept Therapeutics (CORT) reported a Form 144 notice for the proposed sale of 2,200 common shares with an aggregate market value of
Insider transactions by Chief Development Officer William Guyer show simultaneous option exercise and stock sales dated
FAQ
What is the current stock price of Corcept Therapeutics (CORT)?
What is the market cap of Corcept Therapeutics (CORT)?
